Premature dose escalation is one of the most common errors with GLP-1/GIP agonists and is strongly associated with pronounced gastrointestinal side effects and early discontinuation
Some fraudulent suppliers create professional-looking COAs using fake laboratory names or real laboratory names without authorization
All 50 states are served without insurance, and HSA/FSA accounts are eligible for payment
In December 2023, Eli Lilly and Company, one of the major GLP-1 receptor agonist companies, announced the availability of Zepbound (tirzepatide) injection, a GLP-1 drug, in the U.S
Individual factorslike genetics and gut healthinfluence digestive tolerance more than the medication source
Eur Heart J 41(2):255323 Dal Canto E, Ceriello A, Rydn L et al (2019) Diabetes as a cardiovascular risk factor: an overview of global trends of macro and micro vascular complications